<i>Bcl-xL</i> as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in <i>BRAF</i> -mutant stage II and III colon cancer
Philip D. Dunne(Queen's University Belfast), Mark Lawler(Queen's University Belfast)
Cited by 11
Related Papers
Integrating Genomics into Healthcare: A Global Responsibility
|The American Journal of Human Genetics|2019|390
Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges
|Nature Reviews Clinical Oncology|2017|241
European Groundshot—addressing Europe's cancer research challenges: a Lancet Oncology Commission
|The Lancet Oncology|2022|104
ESMO expert consensus statements on the screening and management of financial toxicity in patients with cancer
|ESMO Open|2024|54
A Catalyst for Change: The European Cancer Patient's Bill of Rights
|The Oncologist|2014|46